Lumea and Paige Partner to Advance AI-Powered Digital Pathology
Lumea and Paige partner to integrate AI-powered workflows, enhancing diagnostic efficiency and accessibility in cancer care.
LEHI, UT, UNITED STATES, June 3, 2025 / EINPresswire.com / -- Lumea, the U.S. leader in primary clinical digital pathology, today announced a partnership with Paige, a leader in next-generation AI technology, to expand the integration and impact of AI-powered workflows across pathology practices. This collaboration brings together Lumea's FDA-cleared digital pathology platform with Paige's advanced AI-assisted applications to enhance diagnostic efficiency and accessibility in cancer care.
Through this partnership, Lumea will integrate Paige's AI-assisted diagnostic and biomarker AI software-applications* into its end-to-end digital pathology ecosystem. The combined solution intends to support pathologists in streamlining workflows and enhancing confidence in diagnoses across high-volume clinical settings. By embedding Paige's AI applications within Lumea's high-efficiency infrastructure, the partnership aims to help pathologists deliver faster insights while scaling access to advanced diagnostics.
'Lumea is the proven, secure platform trusted by leading labs to streamline pathology workflows and improve patient outcomes,' said James Thackeray, Lumea CEO. 'Our collaboration with Paige enhances our ability to deliver faster, more precise diagnoses—helping labs boost efficiency, improve outcomes, and maximize ROI.'
Lumea's digital pathology system supports the highest volume of digital cases in the U.S., with significant adoption in urology, dermatology, and gastroenterology. Paige contributes regulatory expertise with the first FDA-cleared AI application in digital pathology*, two additional FDA-breakthrough device designations and state-of-the-art foundation model trained on over a million whole slide images, offering one of the most extensive AI datasets.
'Partnerships like the one we've formed with Lumea are essential to accelerating the adoption of digital pathology and making it a seamless part of routine clinical practice,' said Razik Yousfi, CEO and CTO of Paige. 'By integrating Paige's AI-assisted diagnostic applications into Lumea's platform, we're reducing the friction pathologists often face with new technologies and delivering scalable, real-world solutions that enhance care across diverse clinical settings.'
About Lumea
Lumea is powering efficient, affordable, and accessible digital pathology through simplified, workflow-driven innovation with both tissue-handling technology and a best-in-class viewer with AI-driven workflows. As the U.S. leader in primary clinical digital pathology, processing the highest volume of digital cases nationwide. With over a decade of expertise, Lumea has set the standard for efficiency, quality, and premium cancer diagnostics. With a global presence spanning five continents, Lumea supports over half of the U.S. urology market and top dermatology and gastroenterology groups, optimizing tissue integrity, boosting detection rates, and delivering measurable ROI. By placing patients at the core, Lumea is transforming pathology for a more precise and efficient future. Learn more at www.lumeadigital.com.
About Paige
Paige is pushing the boundaries of AI to solve cancer's most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-cleared AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit www.paige.ai.
* Refer to the product-specific labeling for the regulatory status of each Paige AI-assisted diagnostic application. When Research Use Only (RUO) products are used with regulated products (e.g., FDA-cleared/approved, CE-IVDD, or CE-IVDD), the integrated workflow will be for Research Use Only (RUO) and not for use in diagnostic procedures.
Bianca Collings
Lumea
email us here
Visit us on social media:
LinkedIn
Instagram
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
These Popular Eggs Are Being Recalled Over Salmonella Risk
If you've been living for your morning sunny-side eggs…well, brace yourself. The August Egg Company—the parent behind Sunnyside, Clover, Raley's, and a few other brands—is recalling a whopping 1.7 million dozen eggs due to a potential salmonella outbreak. Yep, it's serious.. The U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention have flagged the August Company's 'brown cage-free and brown certified organic egg' for possible contamination, meaning you might want to double-check that carton in your fridge before cracking it open. If you didn't know, Salmonella is that sneaky bacteria behind food poisoning and can cause anything from mild stomach upset to serious illness. These eggs were shipped to Walmart stores and other grocers in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. They have a best-by date from March 4 to June 19 and food codes P-6562 or CA5330. Not sure if your eggs are on the list? The FDA has a full rundown of all the recalled brands you can check out. And if the cartons in your fridge match any of the food codes or best-by-dates, toss them out immediately. While it's somewhat okay to eat an egg past its expiration date, this isn't the case. The FDA has already connected a current salmonella outbreak to the eggs. As of now, a total of 79 cases have been reported in seven states, while 21 people have been hospitalized. We get it: eggs are pricey, and tossing them feels like a waste. But don't risk it. Plus, most places will give you a full refund. And if your eggs touched any surfaces, wipe those down like your life depends on it. If after eating you feel dizzy, nauseous, or get a fever—don't play it cool. Call your doctor. This is serious business. Trust me, as a four-time survivor of food poisoning, you don't want to take any chances. You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails
Yahoo
2 hours ago
- Yahoo
Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval
Sarepta Therapeutics saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year. This significant increase can be partially attributed to several key announcements, including the FDA's platform technology designation for their rAAVrh74 viral vector, pivotal updates from ongoing studies related to their ELEVIDYS treatment for Duchenne Muscular Dystrophy, and new approval in Japan. These developments highlight the company's continued progress and innovation in gene therapy, reinforcing investor confidence amidst market growth. We've identified 2 weaknesses for Sarepta Therapeutics (1 is a bit concerning) that you should be aware of. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Recent developments for Sarepta Therapeutics have sparked a positive response in short-term share price, primarily driven by advancements in their gene therapy programs. These innovations, particularly the FDA's designation and updates on the ELEVIDYS program, are poised to bolster investor confidence. However, despite this optimism, it's essential to acknowledge that Sarepta's shares have experienced a 37.80% decline over the past three years, highlighting challenges the company has faced. Relative to the biotechnology industry, Sarepta has underperformed in the past year compared to the US Biotechs market, which returned -9.3%. The recent announcements could potentially impact Sarepta's revenue and earnings forecasts considerably. Analysts project a significant annual revenue increase over the next three years, with expectations that profit margins will improve. Crucially, these updates could address operational delays and safety concerns surrounding ELEVIDYS, enhancing the therapy's credibility and market uptake. In terms of valuation, Sarepta's recent share price movements are in the context of an analyst price target of US$89.96, indicating further room for growth if the company's strategic objectives translate into financial success. These factors collectively shape a complex but promising outlook for Sarepta as it navigates both opportunities and challenges in its field. The valuation report we've compiled suggests that Sarepta Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SRPT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval
Sarepta Therapeutics saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year. This significant increase can be partially attributed to several key announcements, including the FDA's platform technology designation for their rAAVrh74 viral vector, pivotal updates from ongoing studies related to their ELEVIDYS treatment for Duchenne Muscular Dystrophy, and new approval in Japan. These developments highlight the company's continued progress and innovation in gene therapy, reinforcing investor confidence amidst market growth. We've identified 2 weaknesses for Sarepta Therapeutics (1 is a bit concerning) that you should be aware of. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Recent developments for Sarepta Therapeutics have sparked a positive response in short-term share price, primarily driven by advancements in their gene therapy programs. These innovations, particularly the FDA's designation and updates on the ELEVIDYS program, are poised to bolster investor confidence. However, despite this optimism, it's essential to acknowledge that Sarepta's shares have experienced a 37.80% decline over the past three years, highlighting challenges the company has faced. Relative to the biotechnology industry, Sarepta has underperformed in the past year compared to the US Biotechs market, which returned -9.3%. The recent announcements could potentially impact Sarepta's revenue and earnings forecasts considerably. Analysts project a significant annual revenue increase over the next three years, with expectations that profit margins will improve. Crucially, these updates could address operational delays and safety concerns surrounding ELEVIDYS, enhancing the therapy's credibility and market uptake. In terms of valuation, Sarepta's recent share price movements are in the context of an analyst price target of US$89.96, indicating further room for growth if the company's strategic objectives translate into financial success. These factors collectively shape a complex but promising outlook for Sarepta as it navigates both opportunities and challenges in its field. The valuation report we've compiled suggests that Sarepta Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SRPT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
